Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alector, Inc.ALEC · Entity 6051 | Chief Medical Officer | August 09, 2021 | August 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alector, Inc.
Report date August 09, 2021 · Filed August 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 234,319 |
Ending reported balance
After 2021-08-09 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-08-09 · Exercise / conversion · Acquired 9,691 · Balance 244,010 Row 2 · 2021-08-09 · Exercise / conversion · Acquired 8,734 · Balance 252,744 Row 3 · 2021-08-09 · Exercise / conversion · Acquired 4,525 · Balance 257,269 Row 4 · 2021-08-09 · Sale · Disposed 22,650 · Balance 234,619 F1: The sales reported by the reporting person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 28, 2020. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.71 to $27.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Row 5 · 2021-08-09 · Sale · Disposed 300 · Balance 234,319 F1: The sales reported by the reporting person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 28, 2020. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.71 to $27.83, inclusive. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.16 · Expires 2028-07-02 | Direct | 81,000 |
Reported balance
After 2021-08-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-09 · Exercise / conversion · Disposed 9,691 · Balance 81,000 F4: Shares subject to the option vest in 48 equal monthly installments beginning on August 2, 2018. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.14 · Expires 2028-11-06 | Direct | 31,250 |
Reported balance
After 2021-08-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-08-09 · Exercise / conversion · Disposed 8,734 · Balance 31,250 F5: One-fourth of the total number of shares subject to the option grant vested on November 1, 2019, and an additional 1/48th of the shares subject vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.15 · Expires 2029-11-06 | Direct | 84,450 |
Reported balance
After 2021-08-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-08-09 · Exercise / conversion · Disposed 4,525 · Balance 84,450 F6: Shares subject to the option vest in 48 equal monthly installments beginning on December 6, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported by the reporting person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 28, 2020.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.71 to $27.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.71 to $27.83, inclusive.
F4: Shares subject to the option vest in 48 equal monthly installments beginning on August 2, 2018.
F5: One-fourth of the total number of shares subject to the option grant vested on November 1, 2019, and an additional 1/48th of the shares subject vest monthly thereafter.
F6: Shares subject to the option vest in 48 equal monthly installments beginning on December 6, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2020 Filed Oct 5, 2020 20:29 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 109,689 | $0.00 Strike: $10.24 | $0.00 |
DisclosureSEC source: 0001209191-20-053606 · doc4.xml · derivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,689 Underlying: Common Stock · 109,689 shares Expires 2030-09-30 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option shall vest on the one month anniversary of October 1, 2020 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the shares shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a service provider to the Issuer through each such date. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:43 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 378 | $23.58 | $8,913.24 |
DisclosureSEC source: 0001209191-20-042869 · doc4.xml · nonDerivative · entry 2 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.56 to $23.61 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:43 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 9,622 | $22.94 | $220,728.68 |
DisclosureSEC source: 0001209191-20-042869 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,097 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.54 to $23.50 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:21 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 3,909 | $29.90 | $116,879.10 |
DisclosureSEC source: 0001209191-20-037254 · doc4.xml · nonDerivative · entry 2 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $29.76 to $30.14 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:21 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 6,091 | $29.43 | $179,258.13 |
DisclosureSEC source: 0001209191-20-037254 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,628 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $28.76 to $29.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2020 Filed May 19, 2020 21:23 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 2,104 | $27.78 | $58,449.12 |
DisclosureSEC source: 0001209191-20-030604 · doc4.xml · nonDerivative · entry 3 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $27.61 to $27.99 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2020 Filed May 19, 2020 21:23 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 5,996 | $27.00 | $161,892.00 |
DisclosureSEC source: 0001209191-20-030604 · doc4.xml · nonDerivative · entry 2 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,823 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $26.60 to $27.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2020 Filed May 19, 2020 21:23 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 1,900 | $26.15 | $49,685.00 |
DisclosureSEC source: 0001209191-20-030604 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,819 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $25.57 to $26.53 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 21:12 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 10,000 | $22.27 | $222,700.00 |
DisclosureSEC source: 0001209191-20-024871 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.86 to $22.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 23:07 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 176 | $24.46 | $4,304.96 |
DisclosureSEC source: 0001209191-20-019776 · doc4.xml · nonDerivative · entry 4 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $24.30 to $24.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 23:07 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 5,459 | $23.49 | $128,231.91 |
DisclosureSEC source: 0001209191-20-019776 · doc4.xml · nonDerivative · entry 3 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,895 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.06 to $24.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 23:07 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 2,884 | $22.47 | $64,803.48 |
DisclosureSEC source: 0001209191-20-019776 · doc4.xml · nonDerivative · entry 2 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,354 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.03 to $23.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 23:07 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 1,481 | $21.57 | $31,945.17 |
DisclosureSEC source: 0001209191-20-019776 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,238 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.03 to $22.01 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 22:00 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 7,000 | $29.74 | $208,180.00 |
DisclosureSEC source: 0001209191-20-010234 · doc4.xml · nonDerivative · entry 2 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $29.45 to $30.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 22:00 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 3,000 | $29.07 | $87,210.00 |
DisclosureSEC source: 0001209191-20-010234 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $28.45 to $29.44 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 01:11 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.16 | $0.00 |
DisclosureSEC source: 0001209191-20-007732 · doc4.xml · derivative · entry 3 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 10,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option vested on August 2, 2018, and an additional one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 01:11 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 10,000 | $32.10 | $321,000.00 |
DisclosureSEC source: 0001209191-20-007732 · doc4.xml · nonDerivative · entry 2 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $32.00 to $32.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 01:11 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionCommon Stock | 10,000 | $8.16 | $81,600.00 |
DisclosureSEC source: 0001209191-20-007732 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 23:14 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $8.16 | $0.00 |
DisclosureSEC source: 0001209191-20-006109 · doc4.xml · derivative · entry 3 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 8,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option vested on August 2, 2018, and an additional one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 23:14 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 8,000 | $28.00 | $224,000.00 |
DisclosureSEC source: 0001209191-20-006109 · doc4.xml · nonDerivative · entry 2 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 23:14 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionCommon Stock | 8,000 | $8.16 | $65,280.00 |
DisclosureSEC source: 0001209191-20-006109 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 22:15 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $8.16 | $0.00 |
DisclosureSEC source: 0001209191-20-005034 · doc4.xml · derivative · entry 4 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,000 Underlying: Common Stock · 6,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option vested on August 2, 2018, and an additional one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 22:15 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 599 | $25.22 | $15,106.78 |
DisclosureSEC source: 0001209191-20-005034 · doc4.xml · nonDerivative · entry 3 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $25.21 to $25.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 22:15 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 5,401 | $24.22 | $130,812.22 |
DisclosureSEC source: 0001209191-20-005034 · doc4.xml · nonDerivative · entry 2 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,318 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $24.00 to $24.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 22:15 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionCommon Stock | 6,000 | $8.16 | $48,960.00 |
DisclosureSEC source: 0001209191-20-005034 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 21:53 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 10,000 | $18.67 | $186,700.00 |
DisclosureSEC source: 0001209191-20-004048 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.25 to $19.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 22:33 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 10,000 | $20.03 | $200,300.00 |
DisclosureSEC source: 0001209191-19-060931 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.65 to $20.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:45 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 10,000 | $15.93 | $159,300.00 |
DisclosureSEC source: 0001209191-19-057201 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $15.47 to $16.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: The shares reported in Column 5 of Table I reflect the adjustments reported in the Reporting Person's Form 4/A filed on November 19, 2019. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 21:30 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $17.15 | $0.00 |
DisclosureSEC source: 0001209191-19-055820 · doc4.xml · derivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-11-05 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option shall vest on the one month anniversary of November 6, 2019 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the shares shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to have a Service Relationship (as defined in the Issuer's 2019 Equity Incentive Plan) with the Issuer through each such date. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:15 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 10,000 | $14.68 | $146,800.00 |
DisclosureSEC source: 0001209191-19-053486 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $14.35 to $14.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 22:33 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $8.16 | $0.00 |
DisclosureSEC source: 0001209191-19-050589 · doc4.xml · derivative · entry 3 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,000 Underlying: Common Stock · 4,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option vested on August 2, 2018, and an additional one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 22:33 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 4,000 | $20.00 | $80,000.00 |
DisclosureSEC source: 0001209191-19-050589 · doc4.xml · nonDerivative · entry 2 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 22:33 UTC | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionCommon Stock | 4,000 | $8.16 | $32,640.00 |
DisclosureSEC source: 0001209191-19-050589 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 21:33 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 10,000 | $19.08 | $190,800.00 |
DisclosureSEC source: 0001209191-19-050106 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.57 to $19.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 20:18 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 916 | $16.00 | $14,656.00 |
DisclosureSEC source: 0001209191-19-046979 · doc4.xml · nonDerivative · entry 2 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 20, 2019 Filed Nov 19, 2019 21:42 UTC Amendment | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionStock Option (right to buy) · Derivative | 916 | $0.00 Strike: $8.16 | $0.00 |
DisclosureSEC source: 0001209191-19-057197 · doc4a.xml · derivative · entry 6 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,000 Underlying: Common Stock · 916 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option vested on August 2, 2018, and an additional one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| August 20, 2019 Filed Nov 19, 2019 21:42 UTC Amendment | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 916 | $16.00 | $14,656.00 |
DisclosureSEC source: 0001209191-19-057197 · doc4a.xml · nonDerivative · entry 4 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 20, 2019 Filed Nov 19, 2019 21:42 UTC Amendment | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionCommon Stock | 916 | $8.16 | $7,474.56 |
DisclosureSEC source: 0001209191-19-057197 · doc4a.xml · nonDerivative · entry 3 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:18 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 1,084 | $16.00 | $17,344.00 |
DisclosureSEC source: 0001209191-19-046979 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,635 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 19, 2019 Filed Nov 19, 2019 21:42 UTC Amendment | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionStock Option (right to buy) · Derivative | 1,084 | $0.00 Strike: $8.16 | $0.00 |
DisclosureSEC source: 0001209191-19-057197 · doc4a.xml · derivative · entry 5 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,916 Underlying: Common Stock · 1,084 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option vested on August 2, 2018, and an additional one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| August 19, 2019 Filed Nov 19, 2019 21:42 UTC Amendment | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 1,084 | $16.00 | $17,344.00 |
DisclosureSEC source: 0001209191-19-057197 · doc4a.xml · nonDerivative · entry 2 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 19, 2019 Filed Nov 19, 2019 21:42 UTC Amendment | Alector, Inc. ALEC · Entity 6051 | Exercise / conversionCommon Stock | 1,084 | $8.16 | $8,845.44 |
DisclosureSEC source: 0001209191-19-057197 · doc4a.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 21:19 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 10,000 | $14.19 | $141,900.00 |
DisclosureSEC source: 0001209191-19-046647 · doc4.xml · nonDerivative · entry 1 Paul Robert · CIK 0001757964 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,719 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $14.00 to $14.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.